05.29.20

Adverum Biotechnologies Announces New INFINITY Phase 2 Trial for DME Drug Candidate

Source: Adverum Biotechnologies

02.10.20

Oculis Announces Positive OCS-01 Phase 2 Data in Patients with Diabetic Macular Edema (DME)

Source: Oculis

02.10.20

Kodiak Sciences Announces Additional Data from Ongoing Phase 1b Study of KSI-301 in Patients With Retinal Diseases

Source: Kodiak Sciences

02.10.20

Oxurion Presentation of Positive Topline Data from a Phase 1 Study Evaluating THR-687 for the Treatment of DME

Source: Oxurion

01.15.20

Genentech/Roche Initiate First Diabetic Macular Edema Phase 3 Trial of the Port Delivery System with Ranibizumab

Source: Genentech

01.07.20

Oxurion Reports Positive Topline Data From Phase 1 Study of THR-687 for Treatment of DME

Source: Oxurion

10.12.19

Kodiak Sciences Announces Data from Ongoing Phase 1b Study of KSI-301 in Patients With Wet AMD, DME and RVO

Source: Kodiak Sciences

10.09.19

Oxurion NV to Provide Business and Clinical Update at AAO and OIS Meetings in San Francisco

Source: Oxurion NV

10.08.19

Genentech/Roche Complete Enrollment in YOSEMITE and RHINE Phase 3 Studies of Faricimab in DME

Source: Genentech

10.07.19

Kodiak Sciences Announces Presentation of Durability Data from Clinical Development Program of KSI-301 in Wet AMD, DME, and RVO at AAO

Source: Kodiak Sciences

View more stories